JP2017061448A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017061448A5 JP2017061448A5 JP2016177434A JP2016177434A JP2017061448A5 JP 2017061448 A5 JP2017061448 A5 JP 2017061448A5 JP 2016177434 A JP2016177434 A JP 2016177434A JP 2016177434 A JP2016177434 A JP 2016177434A JP 2017061448 A5 JP2017061448 A5 JP 2017061448A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- assay
- cancer
- tissue
- tumor tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 56
- 238000003556 assay Methods 0.000 claims 31
- 238000000034 method Methods 0.000 claims 31
- 210000001519 tissue Anatomy 0.000 claims 29
- 229940079593 drug Drugs 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 15
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 9
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 9
- 210000002744 extracellular matrix Anatomy 0.000 claims 9
- 238000012258 culturing Methods 0.000 claims 8
- 102000008186 Collagen Human genes 0.000 claims 6
- 108010035532 Collagen Proteins 0.000 claims 6
- 229920001436 collagen Polymers 0.000 claims 6
- 230000035945 sensitivity Effects 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims 4
- 102000011782 Keratins Human genes 0.000 claims 4
- 108010076876 Keratins Proteins 0.000 claims 4
- 238000004458 analytical method Methods 0.000 claims 4
- 239000012091 fetal bovine serum Substances 0.000 claims 4
- 239000001963 growth medium Substances 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims 4
- 210000004881 tumor cell Anatomy 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000002493 microarray Methods 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 102000007469 Actins Human genes 0.000 claims 2
- 108010085238 Actins Proteins 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 102000016359 Fibronectins Human genes 0.000 claims 2
- 108010067306 Fibronectins Proteins 0.000 claims 2
- 239000007995 HEPES buffer Substances 0.000 claims 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 claims 2
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims 2
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims 2
- 108010054147 Hemoglobins Proteins 0.000 claims 2
- 102000001554 Hemoglobins Human genes 0.000 claims 2
- 108010033040 Histones Proteins 0.000 claims 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 2
- 229930182816 L-glutamine Natural products 0.000 claims 2
- 108060008487 Myosin Proteins 0.000 claims 2
- 102000003505 Myosin Human genes 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 239000012980 RPMI-1640 medium Substances 0.000 claims 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 102000013127 Vimentin Human genes 0.000 claims 2
- 108010065472 Vimentin Proteins 0.000 claims 2
- 238000010256 biochemical assay Methods 0.000 claims 2
- 238000001574 biopsy Methods 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 230000003833 cell viability Effects 0.000 claims 2
- 230000019522 cellular metabolic process Effects 0.000 claims 2
- 230000005754 cellular signaling Effects 0.000 claims 2
- 210000003850 cellular structure Anatomy 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 210000002808 connective tissue Anatomy 0.000 claims 2
- -1 dermicidin Proteins 0.000 claims 2
- 210000003238 esophagus Anatomy 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000004190 glucose uptake Effects 0.000 claims 2
- 210000002216 heart Anatomy 0.000 claims 2
- 238000003364 immunohistochemistry Methods 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 210000000936 intestine Anatomy 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 210000005075 mammary gland Anatomy 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 238000003753 real-time PCR Methods 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 210000002027 skeletal muscle Anatomy 0.000 claims 2
- 229940054269 sodium pyruvate Drugs 0.000 claims 2
- 210000000952 spleen Anatomy 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 229960005322 streptomycin Drugs 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 210000001541 thymus gland Anatomy 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- 210000004291 uterus Anatomy 0.000 claims 2
- 210000005048 vimentin Anatomy 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108090000397 Caspase 3 Proteins 0.000 claims 1
- 102100029855 Caspase-3 Human genes 0.000 claims 1
- 102100026548 Caspase-8 Human genes 0.000 claims 1
- 108090000538 Caspase-8 Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 231100000416 LDH assay Toxicity 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 231100000480 WST assay Toxicity 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000032677 cell aging Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 238000003318 immunodepletion Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 238000002843 lactate dehydrogenase assay Methods 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 238000012205 qualitative assay Methods 0.000 claims 1
- 238000012207 quantitative assay Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3310CH2011 | 2011-10-04 | ||
| IN3310/CHE/2011 | 2011-10-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014534027A Division JP6147259B2 (ja) | 2011-10-04 | 2012-10-04 | Ｅｃｍ組成物、腫瘍微小環境プラットフォームおよびその方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017061448A JP2017061448A (ja) | 2017-03-30 |
| JP2017061448A5 true JP2017061448A5 (enExample) | 2017-06-15 |
| JP6378273B2 JP6378273B2 (ja) | 2018-08-22 |
Family
ID=54261176
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014534027A Expired - Fee Related JP6147259B2 (ja) | 2011-10-04 | 2012-10-04 | Ｅｃｍ組成物、腫瘍微小環境プラットフォームおよびその方法 |
| JP2016177434A Expired - Fee Related JP6378273B2 (ja) | 2011-10-04 | 2016-09-12 | Ｅｃｍ組成物、腫瘍微小環境プラットフォームおよびその方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014534027A Expired - Fee Related JP6147259B2 (ja) | 2011-10-04 | 2012-10-04 | Ｅｃｍ組成物、腫瘍微小環境プラットフォームおよびその方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (7) | US20140228246A1 (enExample) |
| EP (1) | EP2764099B1 (enExample) |
| JP (2) | JP6147259B2 (enExample) |
| AU (1) | AU2012320088C1 (enExample) |
| CA (1) | CA2850274A1 (enExample) |
| CY (1) | CY1120087T1 (enExample) |
| DK (1) | DK2764099T3 (enExample) |
| ES (1) | ES2660975T3 (enExample) |
| HU (1) | HUE036537T2 (enExample) |
| NO (1) | NO2764099T3 (enExample) |
| PT (1) | PT2764099T (enExample) |
| SG (1) | SG11201401183UA (enExample) |
| TR (1) | TR201802420T4 (enExample) |
| WO (1) | WO2013050962A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105593438B (zh) | 2013-05-31 | 2019-07-05 | 伊顿智能动力有限公司 | 用于通过平衡保护来降低动臂跳动的液压系统及方法 |
| AU2014354599A1 (en) * | 2013-11-27 | 2016-06-09 | Research Foundation Of The City University Of New York | Activity enhancing curcumin compositions and methods of use |
| CN103966168B (zh) * | 2014-05-19 | 2017-05-03 | 广州恒迪生物科技有限公司 | 肿瘤活组织体外培养系统及培养方法 |
| WO2016154082A2 (en) * | 2015-03-23 | 2016-09-29 | Tang Yao | Methods of primary tissue culture and drug screening using autologous serum and fluids |
| GB2555252A (en) * | 2015-04-22 | 2018-04-25 | Ono Pharmaceutical Co | Method for extracting lead compound, method for selecting drug discovery target, device for generating scatter diagram, and data visualization method |
| GB201507894D0 (en) * | 2015-05-08 | 2015-06-24 | Imagen Biotech Ltd | Personalised media |
| KR102757122B1 (ko) * | 2015-10-20 | 2025-01-21 | 셀퀴티 인크. | 1차 세포 샘플을 제조하는 방법 |
| CN106047788A (zh) * | 2016-08-22 | 2016-10-26 | 上海逍鹏生物科技有限公司 | 一种适用于高密度细胞培养体系的培养基 |
| GB2555787A (en) | 2016-11-07 | 2018-05-16 | Landberg Goran | Diagnostic methods |
| WO2018148336A1 (en) * | 2017-02-08 | 2018-08-16 | Mitra Rxdx, Inc. | Method of predicting clinical outcome of anticancer agents |
| WO2018185760A1 (en) | 2017-04-05 | 2018-10-11 | Yeda Research And Development Co. Ltd. | Ex-vivo culture system and methods of using same |
| IL257225A (en) | 2018-01-29 | 2018-04-09 | Yeda Res & Dev | Treatment of sarcoma |
| WO2019164951A1 (en) * | 2018-02-22 | 2019-08-29 | Mitra Rxdx, Inc. | Methods of predicting response to temporally sequenced combination therapy |
| GB201818885D0 (en) | 2018-11-20 | 2019-01-02 | Precomb Therapeutics Ag | 3d human cancer model-based combinatiorial drug development method |
| WO2020172591A1 (en) * | 2019-02-22 | 2020-08-27 | Mitra Rxdx, Inc. | A method to predict a patient's response to an anti-cancer drug from an expression level of a set of genes |
| CA3130930A1 (en) * | 2019-03-19 | 2020-09-24 | Kyuson Yun | Methods and systems for evaluation of cell samples |
| CN112961830A (zh) * | 2021-02-25 | 2021-06-15 | 重庆医科大学附属口腔医院 | 口腔鳞癌组织脱细胞基质及其制备方法和应用 |
| CA3219233A1 (en) | 2021-06-06 | 2022-12-15 | Ravid STRAUSSMAN | Combined treatment for cancer |
| CN113774025B (zh) * | 2021-08-26 | 2023-07-14 | 湖南丰晖生物科技有限公司 | 一种结直肠癌顺铂耐药株的构建方法 |
| WO2023067582A1 (en) * | 2021-10-23 | 2023-04-27 | Mazumdar Shaw Medical Foundation | Tumor microenvironment platform comprising oral carcinoma for predicting drug sensitivity, drug resistance and disease progression |
| WO2023244699A1 (en) | 2022-06-15 | 2023-12-21 | SageMedic Corporation | A high-throughput multiplexed viability and proliferation assay |
| PL444462A1 (pl) * | 2023-04-18 | 2024-10-21 | Uniwersytet Medyczny W Białymstoku | Sposób oceny chemiowrażliwości komórek nowotworowych in vitro na leki przeciwnowotworowe i sposób diagnostyki ex vivo nowotworu piersi |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5508188A (en) * | 1994-01-21 | 1996-04-16 | The Regents Of The University Of California | Method of growing cells in a mammal |
| FR2842822B1 (fr) * | 2002-07-26 | 2004-10-01 | Roussy Inst Gustave | Procede de preparation d'une matrice extracellulaire et son utilisation pour la culture de cellules tumorales |
| WO2008060377A2 (en) * | 2006-10-04 | 2008-05-22 | Anthrogenesis Corporation | Placental or umbilical cord tissue compositions |
| US20120213706A1 (en) * | 2009-04-15 | 2012-08-23 | University Of Medicine And Dentistry Of New Jersey | Reconstituted tumor microenvironment for anticancer drug development |
| WO2011148669A1 (ja) * | 2010-05-25 | 2011-12-01 | 株式会社 島津製作所 | 大腸がんマーカービトロネクチン、及び採血試料中のビトロネクチン濃度の分析方法 |
-
2012
- 2012-10-04 SG SG11201401183UA patent/SG11201401183UA/en unknown
- 2012-10-04 HU HUE12838648A patent/HUE036537T2/hu unknown
- 2012-10-04 ES ES12838648.9T patent/ES2660975T3/es active Active
- 2012-10-04 NO NO12838648A patent/NO2764099T3/no unknown
- 2012-10-04 CA CA2850274A patent/CA2850274A1/en not_active Abandoned
- 2012-10-04 EP EP12838648.9A patent/EP2764099B1/en not_active Not-in-force
- 2012-10-04 WO PCT/IB2012/055334 patent/WO2013050962A1/en not_active Ceased
- 2012-10-04 US US14/347,616 patent/US20140228246A1/en not_active Abandoned
- 2012-10-04 TR TR2018/02420T patent/TR201802420T4/tr unknown
- 2012-10-04 DK DK12838648.9T patent/DK2764099T3/en active
- 2012-10-04 AU AU2012320088A patent/AU2012320088C1/en not_active Ceased
- 2012-10-04 JP JP2014534027A patent/JP6147259B2/ja not_active Expired - Fee Related
- 2012-10-04 PT PT128386489T patent/PT2764099T/pt unknown
-
2016
- 2016-09-12 JP JP2016177434A patent/JP6378273B2/ja not_active Expired - Fee Related
-
2018
- 2018-02-21 CY CY20181100194T patent/CY1120087T1/el unknown
- 2018-10-26 US US16/172,606 patent/US20190170730A1/en not_active Abandoned
-
2019
- 2019-05-24 US US16/422,023 patent/US20190383795A1/en not_active Abandoned
- 2019-05-24 US US16/422,045 patent/US20200064333A1/en not_active Abandoned
- 2019-05-24 US US16/422,031 patent/US20190353640A1/en not_active Abandoned
- 2019-05-24 US US16/422,052 patent/US20190383796A1/en not_active Abandoned
- 2019-05-24 US US16/422,059 patent/US20190346428A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017061448A5 (enExample) | ||
| Wang et al. | Breakthroughs and challenges of organoid models for assessing cancer immunotherapy: a cutting-edge tool for advancing personalised treatments | |
| Lim et al. | Single-cell analysis of circulating tumor cells: why heterogeneity matters | |
| Dünker et al. | Implementation of the chick chorioallantoic membrane (CAM) model in radiation biology and experimental radiation oncology research | |
| JP6378273B2 (ja) | Ｅｃｍ組成物、腫瘍微小環境プラットフォームおよびその方法 | |
| Chang et al. | CTP synthase forms the cytoophidium in human hepatocellular carcinoma | |
| Huh et al. | Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination | |
| Matchett et al. | Spatial genomics: mapping human steatotic liver disease | |
| Kim et al. | The future of tumor organoids in precision therapy | |
| JP2017106923A (ja) | 薬物感受性、薬物抵抗性および疾患進行の予測のための組成物および方法 | |
| Park et al. | Exogenous CXCL12 activates protein kinase C to phosphorylate connexin 43 for gap junctional intercellular communication among confluent breast cancer cells | |
| Brlek et al. | TWIST1 upregulation affects E-cadherin expression in brain metastases | |
| Vella et al. | 3D cell culture models in research: applications to lung cancer pharmacology | |
| Hagemann et al. | Therapy testing in a spheroid-based 3D cell culture model for head and neck squamous cell carcinoma | |
| Li et al. | Organoid development and applications in gynecological cancers: the new stage of tumor treatment | |
| Pulianmackal et al. | Monitoring spontaneous quiescence and asynchronous proliferation-quiescence decisions in prostate cancer cells | |
| Abdalkader et al. | Spatiotemporal determination of metabolite activities in the corneal epithelium on a chip | |
| Mauro-Lizcano et al. | High mitochondrial DNA content is a key determinant of stemness, proliferation, cell migration, and cancer metastasis in vivo | |
| Yang et al. | Modeling methods of different tumor organoids and their application in tumor drug resistance research | |
| Unger et al. | Precision cut cancer tissue slices in anti-cancer drug testing | |
| Buckenmeyer et al. | A 3D self-assembly platform integrating decellularized matrix recapitulates in vivo tumor phenotypes and heterogeneity | |
| Castro et al. | Multi-omics qualification of an organ-on-a-chip model of osteolytic bone metastasis | |
| Jarrosson et al. | An avian embryo patient-derived xenograft model for preclinical studies of human breast cancers | |
| Arani et al. | Tumor organoid as a drug screening platform for cancer research | |
| Quotti Tubi et al. | CK2β-regulated signaling controls B cell differentiation and function |